Insider Transactions in Q1 2025 at Avalo Therapeutics, Inc. (AVTX)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2025
|
Mitchell Chan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,167
+50.0%
|
-
|
|
Mar 28
2025
|
Jonathan Goldman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,167
+50.0%
|
-
|
|
Mar 28
2025
|
Samantha Truex Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,167
+50.0%
|
-
|
|
Mar 28
2025
|
Aaron Kantoff Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,167
+50.0%
|
-
|
|
Mar 28
2025
|
Gilla Kaplan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,167
+50.0%
|
-
|
|
Mar 28
2025
|
June Sherie Almenoff Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,167
+50.0%
|
-
|
|
Mar 28
2025
|
Christopher Ryan Sullivan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,285
-30.1%
|
$58,280
$8.46 P/Share
|
|
Mar 28
2025
|
Christopher Ryan Sullivan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,200
+49.99%
|
-
|
|
Mar 28
2025
|
Garry Arthur Neil Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,787
-27.4%
|
$142,296
$8.46 P/Share
|
|
Mar 28
2025
|
Garry Arthur Neil Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
64,867
+49.98%
|
-
|